MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clinical development. Here we demonstrate that while dinaciclib can effectively block cell...
Main Authors: | Robert N Booher, Harold Hatch, Brian M Dolinski, Thi Nguyen, Lauren Harmonay, Ali-Samer Al-Assaad, Mark Ayers, Michael Nebozhyn, Andrey Loboda, Heather A Hirsch, Theresa Zhang, Bin Shi, Carrie E Merkel, Minilik H Angagaw, Yaolin Wang, Brian J Long, Xianlu Q Lennon, Nathan Miselis, Vincenzo Pucci, James W Monahan, Junghoon Lee, Anna Georgieva Kondic, Eun Kyung Im, David Mauro, Rebecca Blanchard, Gary Gilliland, Stephen E Fawell, Leigh Zawel, Alwin G Schuller, Peter Strack |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4188521?pdf=render |
Similar Items
-
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2021-03-01) -
Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
by: David Howard, et al.
Published: (2021-03-01) -
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
by: Shu-Fu Lin, et al.
Published: (2017-01-01) -
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
by: Christin Riess, et al.
Published: (2020-02-01) -
Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
by: Changhong Ke, et al.
Published: (2020-05-01)